To comment to a blog article, select the comment icon at the bottom of the article. Then, simply enter your information and comment in the appropriate fields. Finally, select the "create post" button and follow the anti-spam instructions.

Please do not comment by linking to an external response. This will be added as a reference and mistakenly appear as something the article author submitted.

Blog Index
The journal that this archive was targeting has been deleted. Please update your configuration.
« President-Elect, Henry VanBrocklin invites your input | Main | The SRS community has lost a long-time colleague and friend »

Post-Doctoral Fellowship Opportunity

Eyal Mishani, PhD, Hadassah Medical OrganizationHADASSAH MEDICAL ORGANIZATION

Post-Doctoral Fellowship in Radiochemistry

Dear Fellow,

We, at the Cyclotron/Radiochemistry Facility at the Hadassah University Hospital in Jerusalem, Israel, are looking for a post-doctoral fellow in radiochemistry for a period of 2-3 years. If you have an interest in this position or are acquainted with someone who has a broad-based experience in fluorine-18 and carbon-11 chemistry and automation, please contact me via email. The post-doctoral fellow will be mainly involved in two projects, including (i) development of fluorine-18 labeled ammonium salt derivatives for myocardial perfusion PET-imaging, and (ii) carbon-11, fluorine-18 and iodine-124 labeling of low-MW tyrosine kinase inhibitors (TKIs) for PET imaging of EGFR-positive tumors in oncology. The selected candidate will be granted full scholarship.

The Cyclotron Radiochemistry facility at Hadassah hospital operates two cyclotrons, a small animal-dedicated PET/ CT, and fully equipped radiochemistry and pre-clinical laboratories enabling the production and research of various radiolabeled compounds. The facility personnel includes permanent experienced engineers, chemists and biologists who will support and assist any activity carried out by the selected postdoc candidate.

For further information and submission of CV, please contact Prof. Eyal Mishani at mishani (at)


References (14)

References allow you to track sources for this article, as well as articles that were written in response to this article.

Reader Comments (1)

I understand that a number of centers in Europe have experience with Ga-68 HBED:CC-PSMA. It appears per the abx website that they have three moieties available for production. I am aware of two centers in the United States that are working with and publishing their studies, one at Harvard University and the other at Johns Hopkins. It seems that with the release of Xofigo that there may now be a niche for a prostate imaging agent, and a nice PET agent at that, since one condition for administration of Xofigo is that there be no visceral disease.

PostPost a New Comment

Enter your information below to add a new comment.

My response is on my own website »
Author Email (optional):
Author URL (optional):
Some HTML allowed: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <code> <em> <i> <strike> <strong>